欧洲泌尿外科学会肾细胞癌指南:2019年更新
欧洲泌尿外科学会肾细胞癌指南专家组基于系统评价等标准化方法制定了2019年更新版指南。该更新对肾细胞癌管理相关文献进行了结构化评估,必要时开展符合PRISMA的系统评价,并采用改良GRADE框架形成推荐。指南旨在为肾细胞癌管理提供可靠且透明的当代证据基础。
要点
- 2019年更新采用系统评价与结构化文献评估,方法学严谨。
- 临床实践推荐基于改良GRADE框架制定。
- 转移性肾细胞癌治疗有多项大型RCT支持,证据等级较高。
核心结论
- 2019年肾细胞癌指南由多学科专家组以最高方法学标准更新,为2019年肾细胞癌管理提供最可靠的当代证据基础。
研究设计与样本
- 指南专家组基于系统评价、结构化文献评估及必要时符合PRISMA的系统评价制定,检索Medline、Cochrane图书馆、试验注册库和会议论文集至2018年6月。
主要发现
- 随机对照试验的偏倚风险普遍较低;多数非随机对照试验因临床和方法学异质性无法合并数据。
- 纳入研究多为回顾性、匹配或非匹配队列,基于单中心或多中心数据或国家登记库。
- 转移性肾细胞癌治疗例外,有多项大型随机对照试验,推荐基于较高证据等级。
关键数值与推荐
- 临床实践推荐基于改良GRADE框架制定。
- 证据检索截至2018年6月,纳入随机对照试验、有对照组的回顾性或对照研究、系统评价和荟萃分析。
临床怎么用
- 临床医生应依据该指南的推荐进行肾细胞癌管理,尤其转移性肾细胞癌的推荐有较高等级证据支持。
局限性
- 多数非随机对照研究存在临床和方法学异质性,无法进行数据合并。
- 纳入研究以回顾性队列为主,可能影响证据强度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The European Association of Urology Renal Cell Carcinoma (RCC) Guideline Panel has prepared evidence-based guidelines and recommendations for the management of RCC. OBJECTIVE: To provide an updated RCC guideline based on standardised methodology including systematic reviews, which is robust, transparent, reproducible, and reliable. EVIDENCE ACQUISITION: For the 2019 update, evidence synthesis was undertaken based on a comprehensive and structured literature assessment for new and relevant data. Where necessary, formal systematic reviews adhering to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines were undertaken. Relevant databases (Medline, Cochrane Libraries, trial registries, conference proceedings) were searched until June 2018, including randomised controlled trials (RCTs) and retrospective or controlled studies with a comparator arm, systematic reviews, and meta-analyses. Where relevant, risk of bias (RoB) assessment, and qualitative and quantitative syntheses of the evidence were performed. The remaining sections of the document were updated following a structured literature assessment. Clinical practice recommendations were developed and issued based on the modified GRADE framework. EVIDENCE SYNTHESIS: All chapters of the RCC guidelines were updated based on a structured literature assessment, for prioritised topics based on the availability of robust data. For RCTs, RoB was low across studies. For most non-RCTs, clinical and methodological heterogeneity prevented pooling of data. The majority of included studies were retrospective with matched or unmatched cohorts, based on single- or multi-institutional data or national registries. The exception was for the treatment of metastatic RCC, for which there were several large RCTs, resulting in recommendations based on higher levels of evidence. CONCLUSIONS: The 2019 RCC guidelines have been updated by the multidisciplinary panel using the highest methodological standards. These guidelines provide the most reliable contemporary evidence base for the management of RCC in 2019. PATIENT SUMMARY: The European Association of Urology Renal Cell Carcinoma Guideline Panel has thoroughly evaluated the available research data on kidney cancer to establish international standards for the care of kidney cancer patients.
引用
- Ljungberg B, Albiges L, Abu-Ghanem Y, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update. Eur Urol. 2019. PMID: 30803729. doi:10.1016/j.eururo.2019.02.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。